JP7010473B2 - Ｌｙｍ－１およびｌｙｍ－２標的化ｃａｒ細胞免疫療法 - Google Patents

Ｌｙｍ－１およびｌｙｍ－２標的化ｃａｒ細胞免疫療法 Download PDF

Info

Publication number
JP7010473B2
JP7010473B2 JP2017562598A JP2017562598A JP7010473B2 JP 7010473 B2 JP7010473 B2 JP 7010473B2 JP 2017562598 A JP2017562598 A JP 2017562598A JP 2017562598 A JP2017562598 A JP 2017562598A JP 7010473 B2 JP7010473 B2 JP 7010473B2
Authority
JP
Japan
Prior art keywords
hla
cells
seq
antibody
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017562598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018524973A (ja
JP2018524973A5 (enExample
Inventor
アラン エル． エプスタイン，
Original Assignee
ユニバーシティ オブ サザン カリフォルニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ サザン カリフォルニア filed Critical ユニバーシティ オブ サザン カリフォルニア
Publication of JP2018524973A publication Critical patent/JP2018524973A/ja
Publication of JP2018524973A5 publication Critical patent/JP2018524973A5/ja
Priority to JP2021182547A priority Critical patent/JP2022051570A/ja
Application granted granted Critical
Publication of JP7010473B2 publication Critical patent/JP7010473B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017562598A 2015-06-04 2016-06-03 Ｌｙｍ－１およびｌｙｍ－２標的化ｃａｒ細胞免疫療法 Expired - Fee Related JP7010473B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021182547A JP2022051570A (ja) 2015-06-04 2021-11-09 Ｌｙｍ－１およびｌｙｍ－２標的化ｃａｒ細胞免疫療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562171004P 2015-06-04 2015-06-04
US62/171,004 2015-06-04
PCT/US2016/035916 WO2016197064A1 (en) 2015-06-04 2016-06-03 Lym-1 and lym-2 targeted car cell immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021182547A Division JP2022051570A (ja) 2015-06-04 2021-11-09 Ｌｙｍ－１およびｌｙｍ－２標的化ｃａｒ細胞免疫療法

Publications (3)

Publication Number Publication Date
JP2018524973A JP2018524973A (ja) 2018-09-06
JP2018524973A5 JP2018524973A5 (enExample) 2019-06-13
JP7010473B2 true JP7010473B2 (ja) 2022-02-10

Family

ID=57441999

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017562598A Expired - Fee Related JP7010473B2 (ja) 2015-06-04 2016-06-03 Ｌｙｍ－１およびｌｙｍ－２標的化ｃａｒ細胞免疫療法
JP2021182547A Pending JP2022051570A (ja) 2015-06-04 2021-11-09 Ｌｙｍ－１およびｌｙｍ－２標的化ｃａｒ細胞免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021182547A Pending JP2022051570A (ja) 2015-06-04 2021-11-09 Ｌｙｍ－１およびｌｙｍ－２標的化ｃａｒ細胞免疫療法

Country Status (9)

Country Link
US (2) US10711064B2 (enExample)
EP (1) EP3302559B1 (enExample)
JP (2) JP7010473B2 (enExample)
CN (1) CN107847601A (enExample)
AU (1) AU2016270474A1 (enExample)
CA (1) CA2987992A1 (enExample)
HK (1) HK1253549A1 (enExample)
IL (1) IL256058B (enExample)
WO (1) WO2016197064A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934581B1 (en) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
KR101605421B1 (ko) 2014-03-05 2016-03-23 국립암센터 B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
AU2016209032A1 (en) 2015-01-23 2017-08-10 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3468994A1 (en) * 2016-06-08 2019-04-17 Intrexon Corporation Cd33 specific chimeric antigen receptors
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US20200165342A1 (en) * 2017-02-21 2020-05-28 Eutilex Co., Ltd. Hla-dr car-t compositions and methods of making and using the same
EP3606555A4 (en) * 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES
WO2018204761A1 (en) * 2017-05-05 2018-11-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rapid method for the culture of tumor infiltrating lymphocytes
JP2020523586A (ja) * 2017-06-13 2020-08-06 ベックマン コールター， インコーポレイテッド Ｆｌｕｏ感受性フローサイトメトリーによる白血球由来マイクロベシクルの検出
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CA3109209A1 (en) 2018-08-10 2020-02-13 Eutilex Co., Ltd. Chimeric antigen receptor that binds hla-dr and car-t cell
TWI850282B (zh) * 2018-11-27 2024-08-01 香港商弘年發展有限公司 用於治療癌症之質體建構體和使用方法
MX2021009744A (es) * 2019-02-15 2021-11-12 Univ Southern California Composiciones de anticuerpos lym-1 y lym-2 y constructos car mejorados.
WO2020261231A1 (en) * 2019-06-27 2020-12-30 Eutilex Co., Ltd. Chimeric antigen receptor with 4-1bb costimulatory domain
CN116490518A (zh) 2020-07-17 2023-07-25 西穆尔克斯股份有限公司 用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法
IL313935A (en) * 2021-12-30 2024-08-01 Tr1X Inc CD4+ T cells expressing IL-10 chimeric antigen receptors and uses thereof
CN117186242A (zh) * 2023-07-14 2023-12-08 上海市浦东医院（复旦大学附属浦东医院） 一种靶向vegfr2和pd-1的双靶点嵌合抗原受体及其应用
CN117106098A (zh) * 2023-07-14 2023-11-24 上海市浦东医院（复旦大学附属浦东医院） Vegfr2和pd-1双靶点三代嵌合抗原受体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1737011A (zh) 2004-08-20 2006-02-22 上海美恩生物技术有限公司 抗hla－dr10的淋巴瘤特异性嵌合单抗
CN103041387A (zh) 2011-10-11 2013-04-17 苏州工业园区晨健抗体组药物开发有限公司 恶性b细胞淋巴瘤抗体药物的新用途
JP2015513920A (ja) 2012-04-11 2015-05-18 アメリカ合衆国 Ｂ細胞成熟抗原を標的指向するキメラ抗原受容体

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US707993A (en) 1901-05-16 1902-08-26 Clinton J Warren Machine for corking bottles.
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4724213A (en) 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-1 and diagnostic antibody produced thereby
US4724212A (en) 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-2 and diagnostic antibody produced thereby
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
DE69233367T2 (de) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
SE9101433D0 (sv) 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
EP0590067A1 (en) 1991-06-14 1994-04-06 Xoma Corporation Microbially-produced antibody fragments and their conjugates
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2247204T3 (es) 1994-01-31 2006-03-01 Trustees Of Boston University Bancos de anticuerpos policlonales.
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
AU781396B2 (en) 1999-07-20 2005-05-19 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2001062895A2 (en) 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
CA2439067C (en) 2001-03-13 2011-02-15 Novartis Ag Lentiviral packaging constructs
DK1583830T3 (da) 2003-01-07 2007-01-15 Symphogen As Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner
US20070037741A1 (en) 2003-03-11 2007-02-15 Daryl Baldwin Novel compositions and methods for the treatment of immune related disease
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
JP2007513976A (ja) * 2003-12-15 2007-05-31 デンドレオン コーポレイション Ｈｌａ−ｄｒ特異的抗体、組成物、および方法
GB0408449D0 (en) 2004-04-15 2004-05-19 Banerjee Subhasis Diagnostic and therapeutic applications of soluble lhcge protein
US7527947B2 (en) 2004-06-14 2009-05-05 Novozymes A/S Signal peptide for producing a polypeptide
US20060063209A1 (en) * 2004-08-20 2006-03-23 The Regents Of The University Of California Engineered antibody fragment that irreversibly binds an antigen
AU2006218454B2 (en) * 2005-03-03 2011-11-17 Immunomedics, Inc. Humanized L243 antibodies
WO2007058725A2 (en) * 2005-10-12 2007-05-24 The Regents Of The University Of California Engineered antibody fragment that irreversibly binds an antigen
PL3006459T3 (pl) 2008-08-26 2022-01-17 City Of Hope Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu
NZ592432A (en) 2008-11-03 2013-01-25 Alethia Biotherapeutics Inc Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
ES2816450T3 (es) 2012-02-22 2021-04-05 Univ Pennsylvania Uso de CAR basados en ICOS para mejorar la actividad antitumoral y la persistencia del CAR
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
KR101605421B1 (ko) * 2014-03-05 2016-03-23 국립암센터 B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
AU2016243124A1 (en) 2015-03-27 2017-11-02 University Of Southern California CAR T-cell therapy directed to LHR for the treatment of solid tumors
US20190031759A1 (en) * 2015-04-30 2019-01-31 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
US20200165342A1 (en) * 2017-02-21 2020-05-28 Eutilex Co., Ltd. Hla-dr car-t compositions and methods of making and using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1737011A (zh) 2004-08-20 2006-02-22 上海美恩生物技术有限公司 抗hla－dr10的淋巴瘤特异性嵌合单抗
CN103041387A (zh) 2011-10-11 2013-04-17 苏州工业园区晨健抗体组药物开发有限公司 恶性b细胞淋巴瘤抗体药物的新用途
JP2015513920A (ja) 2012-04-11 2015-05-18 アメリカ合衆国 Ｂ細胞成熟抗原を標的指向するキメラ抗原受容体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH，1987年，vol.47，p.830-840
Journal for ImmunoTherapy of Cancer，2014年，vol.2, no. Suppl 3，P16

Also Published As

Publication number Publication date
EP3302559B1 (en) 2022-01-12
IL256058B (en) 2021-09-30
EP3302559A1 (en) 2018-04-11
IL256058A (en) 2018-01-31
AU2016270474A1 (en) 2018-01-04
US20160355590A1 (en) 2016-12-08
JP2022051570A (ja) 2022-03-31
JP2018524973A (ja) 2018-09-06
WO2016197064A1 (en) 2016-12-08
CA2987992A1 (en) 2016-12-08
HK1253549A1 (zh) 2019-06-21
US20210147551A1 (en) 2021-05-20
CN107847601A (zh) 2018-03-27
EP3302559A4 (en) 2019-02-20
US10711064B2 (en) 2020-07-14

Similar Documents

Publication Publication Date Title
JP7010473B2 (ja) Ｌｙｍ－１およびｌｙｍ－２標的化ｃａｒ細胞免疫療法
US20240392011A1 (en) Hla-g as a novel target for car t-cell immunotherapy
US20250129171A1 (en) Car t-cell therapy directed to lhr for the treatment of solid tumors
US12054543B2 (en) CLDN 18.2-specific monoclonal antibodies and methods of use thereof
US20180118831A1 (en) Car t-cells for the treatment of b7-h4 expressing solid tumors
US20200016201A1 (en) Chimeric antigen receptors and compositions and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190430

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20200309

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20200316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220105

R150 Certificate of patent or registration of utility model

Ref document number: 7010473

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees